Dear Dr. Stone,

I recently had the pleasure of reviewing Angela’s chart and medication profile. In alignment with her goals of preserving her independence, autonomy, and cognitive clarity, I have outlined a few clinical recommendations below for your consideration.

I am always happy to discuss these with you or your team if you have any questions or would like to coordinate a plan.

Key Clinical Findings & Rationale

1. Severe Anticholinergic Antagonism: Patient has been taking OTC Diphenhydramine (25–50 mg QHS) + Tylenol PM regularly for insomnia over the past 4 months. This potent anticholinergic burden (ACB Score = 3) directly antagonizes central cholinesterase inhibition from prescribed Donepezil 10 mg QHS, likely accounting for recent acute cognitive slowing.
2. High Fall Risk / Sedation Load (AGS Beers Criteria®): Daily PRN use of Lorazepam 0.5 mg combined with OTC sedating antihistamines correlates directly with two recent near-fall incidents and pronounced daytime lethargy.
3. Diuretic Timing: Hydrochlorothiazide 25 mg is currently taken at 7:00 PM, inducing nocturia and nighttime fall risks.

Suggested Action Items for Prescriber Consideration

• Lorazepam Taper: Consider initiating a structured, gradual de-escalation/taper of Lorazepam 0.5 mg (e.g., 0.25 mg QHS x 14 days, then discontinue) to reduce CNS/fall risk.
• Donepezil Re-evaluation: Maintain Donepezil 10 mg QHS while allowing a 30-day washout of OTC anticholinergics to assess true baseline cognitive response.
• Omeprazole Review & Labs: Patient has been on continuous PPI therapy for >3 years. Consider step-down therapy and order serum Vitamin B12, Magnesium, and Basic Metabolic Panel.
• Timing Adjustment: Confirm moving Hydrochlorothiazide 25 mg to morning administration.